Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment

Abbreviated Name
PASS: Ref Set App: Cooperberg miRNA (2018)
Lead Investigator
Carroll, Peter R.University of California San Francisco
Coordinating Investigator
No coordinating investigator
Involved Investigators


No abstract availalbe.


The objective of this aim is to leverage
this remarkable resource to follow
plasma miRNAs during the course of
observation. In PASS, plasma samples
have been collected every 6 months for the whole cohort. We hypothesize that we will be able to validate the miRNA signature at diagnosis and/or during the course of AS to predict disease course and thus identify the subset of patients that will eventually show clear disease progression. To explore this hypothesis, we will measure miRNAs in semiannual plasma specimens over a 2.5 year period. To our knowledge, this study would be the first time in any cancer where consecutive miRNA measurements are made to follow a disease course. The rationale for performing such a study is that successful identification of a signature could alter treatment course. One exciting possibility is that such a signature could allow the intensity of surveillance to be customized, specifically allowing many men to minimize the frequency of follow-up via invasive and expensive biopsies. Conversely, earlier detection of progression could lead to intervention before the disease becomes incurable.

Analytic Method

No analytic method available.


Cooperberg is the actual PI


  • No publications available at this time for this protocol.


  • No biomarkers available at this time for this protocol.

Data Collections

  • No data collections available at this time for this protocol.
 Team Project
Protocol ID
Protocol Type
Reference Set
Field of Research
Collaborative Group
Prostate and Urologic Cancers Research Group
Cancer Types
  • Malignant neoplasm of prostate
Phased Status

Associated Forms